The FDA's request for more safety data on Pozen Inc.'s investigational migraine drug Trexima cut the company's stock value by 60 percent Friday. (BioWorld Today)
The FDA's request for more safety data on Pozen Inc.'s investigational migraine drug Trexima cut the company's stock value by 60 percent Friday. (BioWorld Today)
Human Genome Sciences Inc. could earn more than half a billion dollars per terms of a newly formed agreement with Novartis AG on Albuferon (albumin-interferon alpha 2b), a product expected to move into Phase III for chronic hepatitis C by the end of this year. (BioWorld Today)
Human Genome Sciences Inc. could earn more than half a billion dollars per terms of a newly formed agreement with Novartis AG on Albuferon (albumin-interferon alpha 2b), a product expected to move into Phase III for chronic hepatitis C by the end of this year. (BioWorld Today)
The FDA is allowing Tysabri to return to the market in a limited capacity for multiple sclerosis patients, three months after an advisory committee voted unanimously in favor of doing so. (BioWorld Today)
The FDA is allowing Tysabri to return to the market in a limited capacity for multiple sclerosis patients, three months after an advisory committee voted unanimously in favor of doing so. (BioWorld Today)
